We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioo Scientific Launches BRCA1/2 Amplicon Panel
Product News

Bioo Scientific Launches BRCA1/2 Amplicon Panel

Bioo Scientific Launches BRCA1/2 Amplicon Panel
Product News

Bioo Scientific Launches BRCA1/2 Amplicon Panel


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bioo Scientific Launches BRCA1/2 Amplicon Panel"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bioo Scientific has recently launched the NEXTflex™ BRCA1 and BRCA2 Amplicon Panel for FFPE Illumina-Compatible Sequencing, for the detection of clinically relevant somatic mutations in DNA isolated from FFPE samples, to facilitate variant discovery and confirmation.

This kit is a cost-effective, optimized solution offering best-in-class performance for on-target percentage and coverage uniformity.

The NEXTflex BRCA1 and BRCA2 Amplicon Panels are complete kits that include all components necessary for rapidly generating ready-to-sequence libraries, including primer pairs, library prep reagents, size selection beads, and indexed barcodes.

This kit, facilitating the detection of somatic mutations in the BRCA1/2 genes from DNA isolated from FFPE samples, is Bioo Scientific’s most recent addition to its line of BRCA amplicon panels. Previous kits in this line allow identification of germline mutations in DNA isolated from fresh or frozen materials for both Illumina and Ion Torrent-based sequencing.

Advertisement